Jeffrey Kindler, Pfizer's boss abruptly resigns, saying he can't take the pressure from disappointed investors(11)
Business: Research and develop
Andrew Witty, CEO of GlaxoSmithKline, calls on the pharmaceutical industry to do more with less—and still be innovative(1)
Pharmaceuticals: Attack of the biosimilars
Biotechnology drugs are the next target for cheaper versions(5)
Sanofi and Genzyme: Fighting over orphans
The trouble with Sanofi's bid for Genzyme(2)
Hospital mergers: The war of the wards
Investors are eyeing up hospitals around the world(3)
Health care: Best in the world
America spends on health like no one else(7)
Health-care spending: Pass the statins
Health-care spending in rich countries(30)
Health-care reform: Some pay for prevention, but most don't
Why would private health insurers pay to reduce costs to rival insurers?(10)
Japan's drug firms on the move: A homespun elixir
With growth limited at home, Japan’s pharma industry is buying firms abroad(2)
Health insurance in America: Relapse
The battle between politicians and insurers is not over(15)
Health-care reform: Why the Affordable Care Act was important
Insurers can't drop you when you get sick. Or, at least, it's harder(48)
The dialysis business: Stakes in kidneys
The battle over one of medicine’s fastest-growing and least loved markets(11)
A surprising number of companies spend some time in the clinic(21)
Insurance companies and health reform: Diagnosing the problem
Are American health insurers a big part of the cost problem, or not?(34)
Health care costs: How Maryland keeps its costs down
A successful "bending of the cost curve" other states can learn from(29)
Health insurance premium hikes: The insurance death spiral is here
Rate hikes, loss of coverage and rising profits(36)
Pills get smart: Potential encapsulated
Medicines that can talk to doctors herald a new direction for drugs firms(7)
Novartis's bid for Alcon: In the eye
Minority shareholders in Swiss firms have fewer rights than they thought(4)
Health spending: The cost of good health
Where health-care spending is heaviest(32)
Expiring patents are a bitter pill for drug companies(12)
Roche digests Genentech: Back to the lab
The newly expanded pharmaceutical firm bets on old-fashioned research(2)
Business: Generically challenged
The pharmaceuticals industry may yet find inspiration in its old nemesis, the generic-drugs business(0)
Drug firms buy vaccine-makers: Shot in the dark
Pharmaceutical giants may regret their stampede into the vaccine business(4)
Advertisement
Over the past five days
Over the past seven days
Advertisement